)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Fuji Pharma Co Ltd
Fuji Pharma Co Ltd (4554) investor relations material
Fuji Pharma Co Ltd Q4 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2026 earnings summary13 Nov, 2026
Executive summary
FY9/26 net sales rose 20.7% to ¥62,386m; operating profit increased 27.4% to ¥6,355m and ordinary profit rose 38.5% to ¥6,176m.
Profit attributable to owners of parent fell 5.6% to ¥2,831m, reflecting a ¥2,000m investment securities valuation loss and ¥762m impairment loss.
Growth was supported by women's healthcare products, biosimilar launches, global CMO activity and higher hematology and gastroenterology sales.
Financial highlights
Gross profit rose 17.1% to ¥24,321m; gross margin fell to 39.0% from 40.2% amid higher imported-product costs from currency fluctuations.
SG&A increased 13.9% to ¥17,966m, including R&D expense up 21.4% to ¥4,059m; EBITDA rose 19.1% to ¥10,562m.
Comprehensive income was ¥3,450m, up from ¥2,171m in FY9/25.
Outlook and guidance
FY27 forecast: net sales ¥69,190m (+10.9%), operating profit ¥7,420m (+16.8%), ordinary profit ¥6,910m (+11.9%) and net income ¥4,880m (+72.4%).
Domestic growth is expected from Alyssa and biosimilars; overseas expansion centers on Nextstellis in ASEAN through OLIC. R&D expense is expected to increase significantly.
FY9/26 results reached 105.3% of revised net sales forecast, 103.8% of operating profit forecast and 105.0% of ordinary profit forecast.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Fuji Pharma Co Ltd
- Record FY9/25 results underpin further growth and a ¥47 FY9/26 dividend forecast.4554
Q4 2025 - Women's Healthcare growth lifted H1 sales, but higher costs cut operating profit.4554Q2 2023
- Sales rose 5.8%, while operating profit fell 23.8% as SG&A increased.4554Q1 2023
- 9M sales rose 11.4%, but operating profit fell 33.5%; FY2023 forecasts were unchanged.4554Q3 2023
- Women's Healthcare leads FY9/23 growth as FY9/24 guidance targets further gains.4554Q4 2023
- Sales grew 7.5%, while extraordinary gains lifted profit despite an operating loss.4554Q1 2024
- H1 sales grew, but operating profit fell as extraordinary income lifted net income.4554Q2 2024
- 9M sales rose 12.5%, while higher costs cut operating profit and extraordinary gains lifted net income.4554Q3 2024
- Record FY9/24 sales and extraordinary gains; FY9/25 operating profit forecast to grow 25%.4554Q4 2024
Next Fuji Pharma Co Ltd earnings date
Q1 20274 Feb, 2027
Fuji Pharma Co Ltd
Next Fuji Pharma Co Ltd earnings date
Q1 20274 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)